Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.37 |
| ▸ | HTT | P42858 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577533 | 0.68 | METAP2 (0.54) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL276385 | 0.68 | METAP2 (0.54) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL1812613 | 0.68 | MMP2 (0.53) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL28613178 | 0.67 | METAP2 (0.52) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL30946645 | 0.67 | EGFR (0.45) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL3237268 | 0.67 | EGFR (0.45) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL30203848 | 0.67 | METAP2 (0.52) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL28351928 | 0.67 | METAP2 (0.52) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL28745782 | 0.67 | METAP2 (0.52) | MMP2TSHRMETAP2METAP1CHRM1 | |
| SCHEMBL29683153 | 0.67 | METAP2 (0.52) | MMP2TSHRMETAP2METAP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | claimed |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-04-27 | — | — | US | claimed |
| US-11485744-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2022-11-01 | — | — | US | claimed |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | claimed |
| US-20210206782-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-07-08 | — | — | US | claimed |
| CN-112521305-A | Novel high-penetration medicine for treating Parkinson's disease and medicine composition thereof | 苏州泰飞尔医药有限公司 | 2021-03-19 | — | — | CN | claimed |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2018-08-09 | — | — | US | claimed |
| EP-3357926-A1 | TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS | Yu, Chongxi (US) | 2018-08-08 | — | — | EP | claimed |
| US-9969751-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-05-15 | — | — | US | claimed |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-11-23 | — | — | US | claimed |
| EP-2121593-B1 | TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS | YU CHONGXI (US) | 2015-06-17 | — | — | EP | claimed |
| WO-2014139161-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | TECHFIELDS PHARMA CO., LTD. (CN) | 2014-09-18 | — | — | WO | claimed |
| EP-2656879-A1 | Transdermal delivery systems of beta-lactam antibiotics | Yu, Chongxi (US) | 2013-10-30 | — | — | EP | claimed |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2013-01-17 | — | — | US | claimed |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2012-06-21 | — | — | US | claimed |
| EP-2440523-A1 | HIGH PENETRATION COMPOSITIONS OR PRODRUGS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | Yu, Chongxi (US) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142241-A1 | HIGH PENETRATION COMPOSITIONS OR PRODRUGS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS BIOCHEM CO., LTD. (CN) | 2010-12-16 | — | — | WO | claimed |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2010-02-18 | — | — | US | claimed |
| EP-2121593-A1 | TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS | Yu, Chongxi (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008072032-A1 | TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS | YU CHONGXI (US) | 2008-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | MMP2 421/4885TSHR 4732/4885METAP2 624/4885 |
| US-20210206782-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | MMP2 410/4885TSHR 4708/4885METAP2 510/4885 |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | MMP2 678/4885TSHR 4486/4885METAP2 777/4885 |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | MMP2 591/4885TSHR 4030/4885METAP2 763/4885 |
| US-11485744-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | SLC7A1, VIP, HPGDS | MMP2 421/4885TSHR 4732/4885METAP2 624/4885 |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | MMP2 421/4885TSHR 4732/4885METAP2 624/4885 |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | MMP2 410/4885TSHR 4708/4885METAP2 510/4885 |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | MMP2 410/4885TSHR 4708/4885METAP2 510/4885 |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | MMP2 591/4885TSHR 4030/4885METAP2 763/4885 |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | MMP2 421/4885TSHR 4732/4885METAP2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.